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Case report
The three patients with culture-proven Acanthamoeba keratitis presented 12, 15 and 8 months after onset of symptoms with pre-treatment visual acuities of hand movement, 1/60 and 3/60 respectively. The results of in vitro sensitivity testing are summarised in Table 1 . All three patients with Acanthamoeba keratitis were treated initially with only topical PHMB 0.02%. 2) resulted in visual improvement in the three patients.
Cultures of the excised corneal tissues did not reveal the presence of Acanthamoeba in any patient. Cataract formation in cases 1 and 2 could have resulted from chronic intraocular inflammation, as these patients had the longest duration of disease.
Comment
The reason for loss of response to PHMB in our patients is not clear. In vitro susceptibility testing revealed a low minimum inhibitory concentration for PHMB, compared with propamidine and neomycin, in the two isolates studied ( Table 1 ). Reducing the frequency and number of topical drugs used is also a difficult decision in chronic infections such as Acanthamoeba keratitis, since the organism can encyst under unfavourable conditions. Confocal microscopy can help the clinician identify, in vivo, the persistence of trophozoites and cysts of Acanthamoeba in the cornea.s
This would allow a more rational approach to the reduction and cessation of toxic anti-amoebic therapy, reducing the risk of drug toxicity while protecting against recurrence of infection.
In conclusion, our experience indicates that monotherapy with topical PHMB 0.02% should be avoided in chronic Acanthamoeba keratitis. Such infections are best treated using a multi-drug regimen consisting of PHMB or chlorhexidine,9 propamidine or hexamidine, and neomycin. Since information on the ability of various drug combinations to eradicate
Acanthamoeba from the cornea is still accruing, we suggest that excised corneal tissue in such eyes must be submitted for microbiological examination to evaluate treatment efficacy.
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